Skip to main content
TipRanks
Go Ultimate75% OFF

United Therapeutics (UTHR) Revenue by Segment

787 Followers

Revenue by Segment

United Therapeutics reported revenue by segment of $832.50M in Q3 2026, up 6.3% from Q2 2026 and up 4.1% year over year. This is the highest value since 2019.

Separates income from core drug sales, services, licensing, and any organ- or device-related activities to show which parts of the business drive profit and growth. High concentration in a small number of therapies raises patent and competition risk, while a rising share from newer products, services, or recurring programs signals diversification and potential margin improvement.

$0.00$200.00M$400.00M$600.00M$800.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Tyvaso remains the clear revenue engine—its multi‑year climb has slowed and recently flattened amid competitive pressure even as starts/referrals and patient counts hit records; management doubled the sales force and pushed major filings (Tyvaso IPF sNDA, ralinepag NDA), so 2027 approvals could drive a material upside and justify the narrowed path to a ~$4B run‑rate. Legacy drugs (Remodulin, Orenitram, Unituxin) supply a stable base, but near‑term revenue is uncertain given sales lag versus patient metrics and peer uptake risk.

UTHR Revenue by Segment

PeriodOtherTyvasoRemodulinOrenitramUnituxinAdcircaTotal
Q3 2026Sep 30, 2026$4.90M$503.80M$122.00M$145.00M$52.30M$4.50M$832.50M
Q2 2026Jun 30, 2026$6.80M$452.60M$126.30M$125.70M$65.20M$6.70M$783.30M
Q1 2026Mar 31, 2026$5.30M$457.50M$126.60M$135.60M$53.60M$2.90M$781.50M
Q4 2025Dec 31, 2025$6.60M$464.30M$128.00M$121.20M$62.30M$7.80M$790.20M
Q3 2025Sep 30, 2025$6.90M$478.00M$125.90M$131.10M$47.90M$9.70M$799.50M
Q2 2025Jun 30, 2025$5.50M$469.60M$134.70M$123.90M$58.40M$6.50M$798.60M
Q1 2025Mar 31, 2025$5.00M$466.30M$138.20M$120.70M$58.20M$6.00M$794.40M
Q4 2024Dec 31, 2024$5.50M$415.90M$134.50M$107.80M$67.50M$4.70M$735.90M
Q3 2024Sep 30, 2024$5.50M$433.80M$128.30M$113.20M$61.10M$7.00M$748.90M
Q2 2024Jun 30, 2024$4.90M$398.20M$147.30M$107.10M$51.70M$5.70M$714.90M
Q1 2024Mar 31, 2024$6.20M$372.50M$128.00M$106.20M$58.40M$6.40M$677.70M
Q4 2023Dec 31, 2023$3.90M$350.60M$115.10M$84.10M$54.20M$6.80M$614.70M
Q3 2023Sep 30, 2023$1.90M$325.80M$131.10M$92.00M$51.30M$7.30M$609.40M
Q2 2023Jun 30, 2023$0.00$318.90M$127.20M$95.10M$44.30M$7.50M$593.00M
Q1 2023Mar 31, 2023$2.50M$238.40M$121.40M$88.20M$49.10M$7.30M$506.90M
Q4 2022Dec 31, 2022$3.80M$242.30M$122.50M$75.80M$36.70M$10.40M$491.50M
Q3 2022Sep 30, 2022$0.00$257.70M$114.00M$87.50M$46.10M$10.70M$516.00M
Q2 2022Jun 30, 2022$0.00$201.00M$132.00M$79.00M$44.50M$10.40M$466.90M
Q1 2022Mar 31, 2022$10.00M$172.00M$131.70M$82.80M$55.60M$9.80M$461.90M
Q4 2021Dec 31, 2021$0.00$166.50M$118.30M$72.30M$50.00M$8.10M$415.20M
Q3 2021Sep 30, 2021$0.00$164.20M$125.40M$85.20M$55.30M$14.60M$444.70M
Q2 2021Jun 30, 2021$0.00$153.80M$139.80M$76.20M$53.10M$23.60M$446.50M
Q1 2021Mar 31, 2021$0.00$123.00M$130.20M$72.40M$43.90M$9.60M$379.10M
Q4 2020Dec 31, 2020$0.00$131.70M$127.90M$74.00M$29.70M$21.60M$384.90M
Q3 2020Sep 30, 2020$0.00$129.50M$124.50M$74.70M$37.60M$13.80M$380.10M
Q2 2020Jun 30, 2020$0.00$119.20M$119.00M$75.40M$29.00M$19.40M$362.00M
Q1 2020Mar 31, 2020$0.00$102.90M$145.30M$69.00M$26.60M$12.50M$356.30M
Q4 2019Dec 31, 2019$0.00$91.40M$107.40M$50.90M$33.60M$27.80M$311.10M

Related KPIs